DFX Intelligence
Venture Capital Intelligence
Firms, funds, partners, companies and rounds from sworn filings, firm sites and announcements, kept as a graph with a date and a source on every edge. Facts, inferences and estimates are labelled as such. A fund target is never a close, GAV is never dry powder, and a round size is never an investor’s check.
Funds / Redmile Biopharma Investments III, LP
Redmile Biopharma Investments III, LP
Amounts, each with its basis
- Vintage
- 2020basis: form d first sale
- Target
- unknownnot announced
- First close
- unknownnever inferred from a Form D
- Final close
- unknownonly from an announcement or an LP disclosure
- Announced size
- unknown
- Form D offering
- indefinitewhat may be sold, not what was raised; file 021-385117, sworn by the adviser or filed under this vehicle
- Form D sold
- $500Mas of the filing of Jan 4, 2021, 77 investors
- First sale
- Dec 23, 2020
- Reported GAV
- $1.2Bon the Form ADV filed Jul 3, 2024; the fund's assets, never its size or dry powder
- Owners (ADV)
- 330
- Reported on ADV
- Feb 26, 2021 to Jul 3, 2024
Fundraising evidence
Unknown
latest Form D 2021-01-04, older than 15 months (fr-1)
evidence dated Jan 4, 2021. A Form D offering is permission to sell, not a fund in market; an amount sold is never a close; an evergreen offering amended every year is not a raise.
Lifecycle
Mature
vintage 4 to 7 years
age years: 6first sale: 2020-12-23vintage year: $2,020adv gav as of: 2024-07-03vintage basis: form_d_first_saleform d sold usd: $500Mform d offering usd: n/aform d latest filed at: 2021-01-04
The fund's own reporting through time
11 Form ADV filings
| Filed | Type | Gross asset value | Owners | Min. investment | Adviser-owned | Audit | |
|---|---|---|---|---|---|---|---|
| Feb 26, 2021 | Venture Capital Fund | $554M | 116 | $5.0M | 4% | yes | |
| Mar 31, 2021 | Venture Capital Fund | $554M | 117 | $5.0M | 4% | yes | |
| Dec 2, 2021 | Venture Capital Fund | $554M | 117 | $5.0M | 4% | yes | |
| Feb 9, 2022 | Venture Capital Fund | $554M | 117 | $5.0M | 4% | yes | |
| Mar 31, 2022 | Venture Capital Fund | $1.1B | 342 | $5.0M | 5% | yes | |
| May 6, 2022 | Venture Capital Fund | $1.1B | 342 | $5.0M | 5% | yes | |
| Aug 15, 2022 | Venture Capital Fund | $1.1B | 342 | $5.0M | 5% | yes | |
| Mar 31, 2023 | Venture Capital Fund | $1.1B | 329 | $5.0M | 5% | yes | |
| May 5, 2023 | Venture Capital Fund | $1.1B | 329 | $5.0M | 5% | yes | |
| Mar 28, 2024 | Private Equity Fund | $1.2B | 330 | $5.0M | 5% | yes | |
| Jul 3, 2024 | Private Equity Fund | $1.2B | 330 | $5.0M | 5% | yes |
Principals and agents
5 principals on Form D, 1 placement agents
- Redmile Group, LLC Executive Officer
- Jeremy Green Executive Officer
- Redmile Biopharma Investments III (GP), LLC Promoter
- Mike Lee Executive Officer
- Amrit Nagpal Executive Officer
- J.P. Morgan Securities LLC placement agent
Limited partners and their reported performance
0 public LP reports
No public LP has reported this vehicle. The LP tape is read from public pension disclosures (see Limited partners); a fund appears here only when an LP’s report names it.
Investments attributed to this vehicle
0
No investment attributed to this vehicle. The firm’s investments sit on the firm; a fund gets one only when a source names the vehicle.
Timeline
2 events
- Feb 26, 2021Redmile Biopharma Investments III, LP first reported on Form ADV by Redmile Group (Venture Capital Fund), GAV $553,890,000Fund first reported on Form ADV Fact SEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- Jan 4, 2021Redmile Biopharma Investments III, L.P. filed Form D: $500,235,000 sold (indefinite offering), Venture Capital FundForm D filed Fact SEC EDGAR Form D data sets (quarterly)
Evidence
16 observations
Every observation on this vehicle
- Entity type: Limited Partnership Jan 4, 2021 Fact SEC EDGAR Form D data sets (quarterly)
- Form D fund type: Venture Capital Fund Jan 4, 2021 Fact SEC EDGAR Form D data sets (quarterly)
- Form D industry group: Pooled Investment Fund Jan 4, 2021 Fact SEC EDGAR Form D data sets (quarterly)
- Amendment: false Jan 4, 2021 Fact SEC EDGAR Form D data sets (quarterly)
- Revenue range (Form D): Decline to Disclose Jan 4, 2021 Fact SEC EDGAR Form D data sets (quarterly)
- Incorporated: withinFiveYears Jan 4, 2021 Fact SEC EDGAR Form D data sets (quarterly)
- Jurisdiction: DELAWARE Jan 4, 2021 Fact SEC EDGAR Form D data sets (quarterly)
- Amount sold (Form D): $500M Jan 4, 2021 Fact SEC EDGAR Form D data sets (quarterly)
- Exemptions: 06b, 3C, 3C.7 Jan 4, 2021 Fact SEC EDGAR Form D data sets (quarterly)
- First sale: 2020-12-23 Jan 4, 2021 Fact SEC EDGAR Form D data sets (quarterly)
- Indefinite offering: true Jan 4, 2021 Fact SEC EDGAR Form D data sets (quarterly)
- Investors (Form D): 77 Jan 4, 2021 Fact SEC EDGAR Form D data sets (quarterly)
- Minimum investment (Form D): 100,000 Jan 4, 2021 Fact SEC EDGAR Form D data sets (quarterly)
- Securities offered: pooled Jan 4, 2021 Fact SEC EDGAR Form D data sets (quarterly)
- Office address: Letterman Digital Arts Center, One Letterman Drive, Suite D3-300, San Francisco, CA, 94129 Jan 4, 2021 Fact SEC EDGAR Form D data sets (quarterly)
- Year of incorporation: 2020 Jan 4, 2021 Fact SEC EDGAR Form D data sets (quarterly)